India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically. This move comes after supply chain was disrupted due to the coronavirus pandemic exposed the country’s dependence on China and raised the threat of drug shortages.
The program consists of spending on infrastructure for drug manufacturing centers and financial incentives of up to 20 per cent of incremental sales value over the next eight years, according to a government statement.
Currently, India imports almost 70 per cent of its active pharmaceutical ingredients, the chemicals that make a finished drug work, from China. Hubei province, the epicenter of the coronavirus outbreak has been major source of these ingredients. As the world’s single largest exporter of generic drugs, India is responsible for about 20 per cent of the world’s supply.
Source: IBEF
Image Courtesy: Pharmaceutical Technology
You may also like
-
India and Japan Hold First AI Strategic Dialogue in Mumbai to Deepen Technology Cooperation
-
Government Unveils ₹203-Crore TDIP Scheme to Push 6G and Homegrown Telecom Innovation
-
Domestic Capital Powers India’s Real Estate Boom as Q1 2026 Inflows Jump to US$5.1 Billion
-
Indian Aviation May Handle 500 Million Passengers a Year by 2030, Says NMIA Chief
-
India Pushes ‘Insurance for All’ Agenda with Wider Coverage, Lower Costs and Major Reforms
